Galina Lukina

Prof. Galina Lukina


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
DNDiana S. Novikova
Diana S. Novikova
TVTatyana Popkova V.
Tatyana Popkova V.
GLGalina Lukina
Galina Lukina
ELElena L. Luchikhina
Elena L. Luchikhina
DKDmitry E. Karateev
Dmitry E. Karateev
ENEvgeny L. Nasonov
Evgeny L. Nasonov
Novikova DS, et al. J Korean Med Sci. 2016 Feb;31(2):202-207. http://dx.doi.org/10.3346/jkms.2016.31.2.202

16 February 2016 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
KCKaterina Chatzidionysiou
Katerina Chatzidionysiou
ELElisabeth Lie
Elisabeth Lie
ENEvgeny Nasonov
Evgeny Nasonov
GLGalina Lukina
Galina Lukina
MHMerete Lund Hetland
Merete Lund Hetland
RVRonald F. van Vollenhoven
Ronald F. van Vollenhoven
The approved dose of rituximab (RTX) in rheumatoid arthritis is 1000 mg × 2, but some data have suggested similar clinical efficacy with 500 mg × 2. The purpose of this study was to compare the effectiveness of the regular and low doses given as first treatment course. Twelve European registries participating in the CERERRA collaboration (The European Collaborative Registries for the Evaluation of Rituximab in Rheumatoid Arthritis) submitted anonymized datasets with demographic, efficacy and treatment data for patients who had started RTX. Treatment effectiveness was assessed by DAS28 reductions and EULAR responses after 6 months. Data on RTX dose were available for 2,873 patients, of whom 2,625 (91.4 %) and 248 (8.6 %) received 1000 mg × 2 and 500 mg × 2, respectively. Patients treated with 500 mg × 2 were significantly older, had longer disease duration, higher number of prior DMARDs, but lower number of prior biologics and lower baseline DAS28 than those treated with 1000 mg × 2. Fewer patients in the low-dose group received concomitant DMARDs but more frequently received concomitant corticosteroids. Both doses led to significant clinical improvements at 6 months. DAS28 reductions at 6 months were comparable in the 2 dose regimens [mean DeltaDAS28 ± SD -2.0 ± 1.3 (high dose) vs. -1.7 ± 1.4 (low dose), p = 0.23 adjusted for baseline differences]. Similar percentages of patients achieved EULAR good response in the two dose groups, 18.4 % vs. 17.3 %, respectively (p = 0.36). In this large observational cohort initial treatment with RTX at 500 mg × 2 and 1000 mg × 2 led to comparable clinical outcomes at 6 months.

27 October 2017 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
HUHelen V. Udachkina
Helen V. Udachkina
DNDiana S. Novikova
Diana S. Novikova
TVTatyana Popkova V.
Tatyana Popkova V.
IKIrina G. Kirillova
Irina G. Kirillova
EMEvgenia I. Markelova
Evgenia I. Markelova
ENEugeniy L. Nasonov
Eugeniy L. Nasonov

30 November 2023 in Joint Bone Spine
Verified
Journal Article
Open access
KLKim Lauper
Kim Lauper
DMDenis Mongin
Denis Mongin
SBSytske Anne Bergstra
Sytske Anne Bergstra
DCDenis Choquette
Denis Choquette
CCCatalin Codreanu
Catalin Codreanu
CGCem Gabay
Cem Gabay
To evaluate and compare the use of oral glucocorticoids with three classes of bDMARDs in patients with rheumatoid arthritis (RA). We included patients from 13 observational registries treated with a TNF-inhibitor, abatacept or tocilizumab and with available information on the use of oral glucocorticoids. The main outcome was oral glucocorticoid withdrawal. A McNemar test was used to analyse the change in the use of glucocorticoids after 1 year. Kaplan-Meier estimates and Cox regressions, adjusted for patient, treatment, and disease characteristics, were used to evaluate glucocorticoid discontinuation in patients with glucocorticoids at baseline. Because of heterogeneity, analyses were done by registers and pooled using random-effects meta-analysis. A total of 12,334 participants treated with TNF-inhibitors, 2100 with tocilizumab and 3229 with abatacept were included. At one-year, oral glucocorticoid use decreased in all treatment groups (odds ratio for stopping vs. starting of 2.19 [95% CI 1.58; 3.04] for TNF-inhibitors, 2.46 [1.39; 4.35] for tocilizumab; 1.73 [1.25; 2.21] for abatacept). Median time to glucocorticoid withdrawal was ≈2 years or more in most countries, with a gradual decrease over time. Compared to TNF-inhibitors, crude hazard ratios of glucocorticoid discontinuation were 0.65[0.48-0.87] for abatacept, and 1.04 [0.76-1.43] for tocilizumab, and adjusted hazard ratios were 1.1 [0.83-1.47] for abatacept, and 1.30 [0.96-1.78] for tocilizumab. After initiation of a bDMARD, glucocorticoid use decreased similarly in all treatment groups. However, glucocorticoid withdrawal was much slower than advocated by current international guidelines. More effort should be devoted to glucocorticoid tapering when low disease activity is achieved.

24 June 2020 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
AAAnastasia Avdeeva
Anastasia Avdeeva
AMA. S. Misiyuk
A. S. Misiyuk
ASA. M. Satybaldyev
A. M. Satybaldyev
GLGalina Lukina
Galina Lukina
VSV. N. Sorotskaya
V. N. Sorotskaya
ENE. L. Nasonov
E. L. Nasonov
Objective: to analyze the results of tofacitinib (TOFA) therapy in real clinical practice according to the All-Russian Arthritis Registry (OREL). Subjects and methods. The OREL Registry included 347 patients (286 (82%) women and 61 (18%) men) with rheumatoid arthritis (RA) who initiated TOFA therapy. The male:female ratio was 1:4.7. The patients’ median age at onset of the disease was 42 years; its duration was 8 years. Most of the patients included in the registry had extended- (n=171 (52%)) or late- (n=148 (45%)) stage of RA. Results and discussion. Prior to initiation of TOFA therapy, RA activity according to DAS28 was high and moderate in 91 (64.5%) and 40 (28.4%) patients, respectively; the median DAS28 value was 5.5 [4.6; 6.2]; SDAI – 30.5 [21.4; 42.9], and CDAI – 28.2 [20.0; 37.1]. The use of TOFA was accompanied by significant decrease of disease activity. After 12 weeks, high RA activity was persistent in 32 (22.7%) patients; the number of patients with moderate activity increased to 77 (54.6%), that of those with low activity rose to 15 (10.6%); remission was observed in 17 (12.1%) patients. 216 (62.6%) and 76 (22%) patients received TOFA as first- and second-line therapy, respectively. TOFA was most frequently prescribed when tumor necrosis factor-á inhibitors (19.6%), rituximab (7.8%), tocilizumab (4.3%), and abatacept (5.2%) were insufficiently effective or poorly tolerated. Conclusion. The results of using TOFA in real clinical practice may suggest that the drug has high efficacy in patients with RA. TOFA can be used at a dose of 5 or 10 mg twice daily as both alone and in combination with disease-modifying anti-rheumatic drugs. TOFA showed similar efficacy in patients who had earlier taken biological agents and in those who had not.

15 February 2021 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
EAE. N. Aleksandrova
E. N. Aleksandrova
ANA. A. Novikov
A. A. Novikov
GLGalina Lukina
Galina Lukina
APA. I. Parfenov
A. I. Parfenov
Inflammatory bowel disease IBD (Crohns disease CD, ulcerative colitis UC) immune-mediated diseases of the digestive tract of unknown etiology. The basis of the pathogenesis of IBD is a violation of the protective mechanisms of the intestinal barrier as a result of a complex interaction of environmental factors, a genetic predisposition and defects in the activation of the immune response in the lymphoid tissue of the intestinal mucosa. Three groups of antibodies are detected in the sera of IBD patients: autoantibodies, antimicrobial antibodies and antibodies to peptide antigens. In CD, the most useful diagnostic markers are ASCA; in UC patients pANCA. Antibodies are not among the diagnostic criteria for CD and UC, the diagnosis of which is traditionally made on the basis of a complex of clinical, radiological, endoscopic and histological signs, but can be used as useful additional non-invasive markers for early diagnosis, assessment of clinical phenotypes, prognosis and effectiveness of treatment of these diseases.